Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence.

Jacob LisenoBrittney Lager Catherine MillerSai L ShankarJason P Mendoza James B Lewin

Published in: Neurology and therapy (2021)

This real-world analysis of DRF-treated patients showed high overall persistence, low discontinuation rate due to GI AEs, and high adherence to therapy, aligning with expectations based on DRF clinical trials. Data were consistent in the DMF-to-DRF subgroup. INFOGRAPHIC.

Keyphrases

multiple sclerosis
clinical trial
newly diagnosed
end stage renal disease
ejection fraction
prognostic factors
randomized controlled trial
type diabetes
metabolic syndrome
bone marrow
glycemic control
patient reported outcomes
open label
patient reported